The partnership follows a strategic collaboration between Twist and LakePharma, announced last week, that involves the same technology.
The company said the financing will further support its strategy of translating its genome editing platforms into potential therapeutics and drug-discovery solutions.
With metagenomics, genomics, and other analyses, researchers saw a potential antifungal compound called cyphomycin produced by Streptomyces in an ant in Brazil.
The new entity will offer comprehensive genomic services for precision medicine and drug discovery for central nervous system diseases.
In development for several years, PORTIN is now being deployed as a single point of reference for all genotype and phenotype data at Bayer's research sites.
The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.
The financing round will support uBiome's ongoing efforts to commercialize its clinical microbiome analysis, sexually-transmitted disease, and gut wellness tests.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
Elucidata, which makes software to support drug discovery, recently released a metabolomics analysis platform that includes machine learning technology.
The UK-based Dementia Discovery Fund is investing $1.3M in Immuneering's drug-discovery technology in search of new molecular entities for treating Alzheimer's.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.